Showing 1411-1420 of 1477 results for "".
- Oxford Biomedica Snags Manufacturing Equipment to Ramp Up Production of COVID-19 Vaccinehttps://modernod.com/news/oxford-biomedica-snags-manufacturing-equipment-to-ramp-up-production-of-covid-19-vaccine/2477880/In the race for a COVID-19 vaccine, the University of Oxford has stormed to an early lead with the commercial manufacturing support of British drugmaker AstraZeneca. Now, in an effort to scale up capacity for global demand, one of AstraZeneca’s manufacturing partners has struck a deal for n
- Atia Vision Closes Second Tranche Of $20M In Series D Financinghttps://modernod.com/news/atia-vision-closes-second-tranche-of-20m-in-series-d-financing/2477793/Atia Vision, which is developing of a modular presbyopia-correcting accommodating IOL, announced the closing of its second tranche of a Series D $20M financing. The financing will be used to continue early clinical experience treating cataract patients and support ex
- MPR and MacuLogix Received A’Design Awardhttps://modernod.com/news/mpr-and-maculogix-received-adesign-award/2477781/MPR and MacuLogix were recognized with the A’Design Platinum Award, the world’s largest design competition, for its work on the AdaptDx Pro, a medical headset by MacuLogix. Launched earlier this year, the device build
- Moderna Secures FDA Approval to Advance Coronavirus Vaccine Candidate mRNA-1273 to Phase 2 Testinghttps://modernod.com/news/moderna-secures-fda-approval-to-advance-coronavirus-vaccine-candidate-mrna-1273-to-phase-2-testing/2477729/Moderna said the FDA is allowing it to move ahead with a phase 2 study of its experimental COVID-19 vaccine mRNA-1273. Moderna stated that it will begin the study with 600 participants “shortly” and is finalising the protocol for a phase 3 trial to start early this summer, with CEO St
- White House and Senate Strike a Deal on $2 Trillion Coronavirus Stimulus Billhttps://modernod.com/news/white-house-and-senate-strike-a-deal-on-historic-2-trillion-coronavirus-stimulus-bill/2477454/The White House and Senate leaders reached a deal early Wednesday on a massive $2 trillion relief bill—said to be the largest rescue package in American history—to combat the economic impact of the coronavirus outbreak, according to a CNBC
- FDA Authorizes Hand-Held COVID-19 Diagnostic Testhttps://modernod.com/news/fda-authorizes-hand-held-covid-19-diagnostic-test/2477452/In response to the coronavirus crisis, we’ve seen COVID-19 diagnostics quickly evolve from early, multistep kits to high-throughput versions to fast point-of-care tests, all in just a few weeks. Now, the FDA has granted an emergency authorization to a device that fits in the palm of you
- Doctors Turn to Malaria Drugs as Potential Coronavirus Treatmenthttps://modernod.com/news/doctors-turn-to-malaria-drugs-as-potential-coronavirus-treatment/2477434/Doctors and hospitals are turning to chloroquine phosphate and hydroxychloroquine to treat patients infected with COVID-19, as the antimalarial drugs have both shown early signs of improving symptoms of some patients diagnosed with COVID-19, based on reports by doctors and researchers in South Ko
- Microstent Reduces Post-Cataract Surgery Intraocular Pressure in Glaucoma Patientshttps://modernod.com/news/microstent-reduces-post-cataract-surgery-intraocular-pressure-in-glaucoma-patients/2477293/Microstent implantation in Schlemm’s canal reduces early postoperative IOP following cataract surgery in patients with mild or moderate glaucoma, according to findings from the HORIZON study of the Hydrus microstent, according to a Reuters
- Exonate Announces Collaboration With Janssen to Develop a New Eye Drop for the Treatment of Retinal Vascular Diseaseshttps://modernod.com/news/exonate-announces-collaboration-with-janssen-to-develop-a-new-eye-drop-for-the-treatment-of-retinal-vascular-diseases/2477223/Exonate, an early stage biotechnology company, announced that it has entered into a strategic collaboration agreement with Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. Through the collaboration, Exonate will work with Janssen Research & Development scientists to develop an
- Gemini Therapeutics Enrolls First Patient in Phase 1 Study of GEM103 for Dry AMDhttps://modernod.com/news/gemini-therapeutics-enrolls-first-patient-in-phase-1-study-of-gem103-for-dry-amd/2477214/Gemini Therapeutics announced it has initiated enrollment in its phase 1 study of GEM103, a recombinant, native Complement Factor H (CFH) for the treatment of dry age-related macular degeneration. AMD is the leading cause of irreversible blindness in the western world—affecting millions of